Radius Health, Inc. ( RDUS ) was a big mover last session with its shares rising roughly 7% on the day. The upside was owing to the company's announcement of positive top line data for its osteoporotic fracture candidate from the first six months of the ACTIVExtend trial and 25-month combined data from ACTIVE and ACTIVExtend. This development led to far more shares changing hands yesterday than in a normal session. The move breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $46.63 to $49.43.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Radius Health currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the Med-Drugs industry is Valeant Pharmaceuticals International, Inc. ( VRX ) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
RADIUS HEALTH (RDUS): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
